Slide 1: Q3 2023 Earnings call presentation
st Redcare Q3 2023 Earnings call presentation. @SEVENUM! 31 OCTOBER 2023)
Slide 2: Presenting live from our headquarters
p*: Presenting live from our headquarters.
Slide 3: Presenters
presenters. Jasper Eenhorst, Olaf Heinrich, Chief Financial Officer. Chief Executive Officer. A]
Slide 4: Today's agenda
Today’s agenda. Ci) Financial performance. C2) Update on business and strategy. €&> Outlook and guidance. I]
Slide 5: Financial performance
Financial performance.
Slide 6: 9M 2023 highlights
@ FINANCIAL PERFORMANCE 9M 2023 highlights. > Fast organic and non-organic growth. Total sales up 67% in Q3 and 45% YTD (excl. MediService: 26% in Q3 and 24% YTD). Non-Rx growth of 27% in Q@3 and 26% YTD. > Continued gain in active customers. +0.4M in Q3 and 1.6My.o.y. to 10.5M. NPS (Customer Satisf
Slide 7: Double-digit growth continues across the Group
Double-digit growth continues across the Group. Total DACH International +44.6% i EUR 254M EUR 877M 9M 2022 9M 2023 9M 2022 9M 2023 9M 2022 9M 2023
Slide 8: Continuously strong net promoter score, basket value up
Continuously strong net promoter score, basket value up. Number of customers (NPs) & 7 Not just Net Promoter Score [#GSiiS Q3 2023 (2022: 73) 10.5M ® 8.9M +1.6M € 60.21 Average Shopping Basket Value Sep 2022 Sep 2023 Q@3 2023 (2022: 59.75) I]
Slide 9: Customer loyalty remains high, orders up 1.4 million
@ NON-FINANCIAL KPIs Customer loyalty remains high, orders up 1.4 million. Share of repeat orders Number of orders in percentage of total in millions 56 6.2 5.4 . 4.7 4.2 4.0 4.0 a Os 81% | esa) ce | ef | Ge ee | ai Q2 Q3 Q4 ai Q2 Q3 Q4 2020 2021 Orders: sales to end-customers / patients (B2C) both
Slide 10: Key Financials | Profit & Loss
@ KEY FINANCIALS | PROFIT&LOSS _) Group adj. EBITDA EUR 37 million, up EUR 46 million. MediService included since mid-Q2. in millions of euros, adjusted numbers Sales Gross profit margin Selling & distribution margin Administrative cost margin Adj. EBITDA margin Adj. EBITDA EBITDA Q3 2022 285 28.1%
Slide 11: Adj. EBITDA from -1% to +2.9%, up across the Group
@ KEY FINANCIALS | PROFIT &LOSS ) Adj. EBITDA from -1% to +2.9%, up across the Group. Total Redcare 4 -1.0% 9M 2022 9M 2023 1 DACH segment International Segment ome —#3.7PP 1.4% 9M 2022 9M 2023 9M 2022 9M 2023 -9.6%
Slide 12: Key Financials | Gross Profit Margin
@ KEY FINANCIALS | GROSS PROFIT MARGIN ) Adjusted gross profit margin in percentage of sales 0.8 (0.4) (0.0) 27.4% 28.1% 9M 2022 Product Margin Country / Other 9M 2023 9M 2023 Q3 2022 Q3 2023 Q3 2023 (incl. Mix) REOUS ME including including MediService MediService 12 |
Slide 13: Key Financials | Selling & Distribution Ratio
@ KEY FINANCIALS | SELLING & DISTRIBUTION RATIO ) Efficiency and savings across the Group. Adjusted S&D costs in percentage of sales (24.2%) (25.2%) 2.4 0.2 0.5 (0.0) o (22.0%) (21.4%) (19.4%) (17.0%) 9M 2022 Marketing Shippingand Operational Other 9M 2023 9M 2023 Q3 2022 Q3 2023 @3 2023 Packaging L
Slide 14: Key Financials: Cash Flow
@ KEY FINANCIALS: CASH FLOW Cash management on plan. Cash flow in millions of euros 34 180 31 Dec 2022 Cash and Operating result short-term adjusted for financial assets depreciation, taxes and provisions 14 35 Working capital movements (42) Investments 19 226 30 Sep 2023 Financing and Cash and fore
Slide 15: Business and strategy
business and strategy.
Slide 16: Business and strategy highlights
@ UPDATE ON BUSINESS & STRATEGY ) Business and strategy highlights. > Celebrating three months of our new corporate brand. > Recent visual relaunch of our webshops in Germany and Austria. > Decisive developments on e-Rx in Germany. 16 G
Slide 17: Successful relaunch in Germany and Austria
@ UPDATE ON NEW BRAND Successful relaunch in Germany and Austria. > New visual design, reflecting our corporate approach. >» Local hero names kept. > Overall high acceptance by our customers. 17 s1ShopApotheke I]
Slide 18: 8.000.000 80.000 7.000.000 70.000 6.000.000 60.000 5.000.000 50.000 4.000.000 40.000 3.000.000 30.000 2.000.000 20.000
8.000.000 80.000 7.000.000 70.000 6.000.000 60.000 5.000.000 50.000 4.000.000 40.000 3.000.000 30.000 2.000.000 20.000 1.000.000 10.000 0 0
Slide 19: Update on e-Rx: Current ways to submit e-prescriptions
@ UPDATE ON E-RX Current ways to submit e-prescriptions. Gere fee fo 19 SINCE 1 JULY. Discriminatory way since not suitable for online pharmacy customers. Restricts patients’ free choice of pharmacy. Since plug-in is needed, disadvantage for immobile patients and people living in rural areas. I]
Slide 20: Our fully-digital answer: eGK NFC mobile solution
Our fully-digital answer for Presenting the eGK NFC mobile solution. A non-discriminatory way of redeeming e-prescriptions compared to eGK plug-in. Safe and straight-forward, both ways require a card, but no PIN. No statutory changes for eGK NFC mobile needed. Ongoing talks with gematik, BMG and oth
Slide 21: Outlook and guidance
Outlook and guidance.
Slide 22: Raised guidance
Raised guidance 22 Non-Rx growth 20-30% Total net sales EUR 1.7-1.8 billion. Adj. EBITDA margin 1.5-3% Free cash flow EUR -20M to 20M Mid- to longer-term guidance of adjusted EBITDA margin in excess of 8% unchanged. r
Slide 23: Questions
¥ Redcare questions. ask
Slide 24: Thank you
Thank fe | you. a @SEVENUM I 31 OCTOBER 2023) Redcare